Famitinib

Generic Name
Famitinib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C23H27FN4O2
CAS Number
1044040-56-3
Unique Ingredient Identifier
768FW21J3L
Background

Famitinib has been used in trials studying the treatment of Colorectal Cancer, Renal Cell Cancer, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, and Metastatic Renal Cell Cancer, among others.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

First Posted Date
2024-07-23
Last Posted Date
2024-12-12
Lead Sponsor
Fudan University
Target Recruit Count
130
Registration Number
NCT06516289
Locations
🇨🇳

Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.

First Posted Date
2024-03-12
Last Posted Date
2024-03-12
Lead Sponsor
Harbin Medical University
Target Recruit Count
40
Registration Number
NCT06306560

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

First Posted Date
2023-03-08
Last Posted Date
2024-02-06
Lead Sponsor
Fudan University
Target Recruit Count
223
Registration Number
NCT05760378
Locations
🇨🇳

Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

First Posted Date
2022-10-26
Last Posted Date
2024-10-04
Lead Sponsor
Fudan University
Target Recruit Count
620
Registration Number
NCT05594095
Locations
🇨🇳

Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

First Posted Date
2022-10-17
Last Posted Date
2024-08-06
Lead Sponsor
Fudan University
Target Recruit Count
716
Registration Number
NCT05582499
Locations
🇨🇳

Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Single Dose Study To Study The Absorption, Metabolism And Excretion Of Famitinib

Phase 1
Active, not recruiting
Conditions
Healthy Subjects
Interventions
Drug: Famitinib
First Posted Date
2022-07-26
Last Posted Date
2022-11-02
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
6
Registration Number
NCT05473468
Locations
🇨🇳

Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

First Posted Date
2022-01-04
Last Posted Date
2024-12-17
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
46
Registration Number
NCT05176080
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

First Posted Date
2021-11-03
Last Posted Date
2023-08-16
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
1
Registration Number
NCT05106335
Locations
🇨🇳

Subei People's Hospital of Jiangsu Province, Yangzhou, Jiangsu, China

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

First Posted Date
2021-08-25
Last Posted Date
2021-08-25
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
30
Registration Number
NCT05020925
Locations
🇨🇳

Cancer Hospital of Guangzhou Sun Yat-sen University, Guangzhou, Guangdong, China

A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.

Phase 2
Conditions
NSCLC
Interventions
Drug: Camrelizumab
Drug: Famitinib
First Posted Date
2021-08-13
Last Posted Date
2021-08-13
Lead Sponsor
Shanghai Chest Hospital
Target Recruit Count
61
Registration Number
NCT05005468
Locations
🇨🇳

Shanghai Chest Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy